Answers are grounded in this paper and cite their sources.
Reveals the development of Drpitor1a targeting Drp1-driven mitochondrial fission in smooth muscle cells, highlighting a potential therapy for pulmonary arterial hypertension.
Drp1 (dynamin-related protein 1), a large GTPase, mediates the increased mitochondrial fission, which contributes to hyperproliferation of pulmonary artery smooth muscle cells in pulmonary arterial hypertension (PAH). We developed a potent Drp1 GTPase inhibitor, Drpitor1a, but its specificity, pharmacokinetics, and efficacy in PAH are unknown.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: